BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing

Investor logo

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

MUSILOVÁ Milena RÁZGA Filip JURČEK Tomáš JEŽÍŠKOVÁ Ivana BORSKÝ Marek NÉMETHOVÁ Veronika ŽÁČKOVÁ Daniela ČULEN Martin DVOŘÁKOVÁ Dana MAYER Jiří RÁČIL Zdeněk

Year of publication 2014
Type Article in Periodical
Magazine / Source American Journal of Hematology
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1002/ajh.23794
Field Oncology and hematology
Keywords BCR-ABL; CD34+; CML; next generation sequencing
Attached files
Description Mutations in the BCR-ABL1 kinase domain (KD) represent one of the most important causes of resistance to tyrosine kinase inhibitors (TKIs) treatment in patients with chronic myeloid leukemia (CML). The resistance-causing mutations are hypothesized to expand directly from the stem and/or progenitor cells and are present in CD341 cells significantly earlier than they occur in bone marrow or peripheral blood. Thus, early detection of these mutations is of great importance, since it can affect the subsequent TKI therapy.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info